MN-ENTRUST
14.9.2020 15:29:04 CEST | Business Wire | Press release
Entrust Datacard today announced a new brand identity and company name – Entrust . The move both continues the company’s enduring leadership and innovation in identity, payments, and data protection, and highlights Entrust’s position as a leader in developing the core technologies needed to keep the world moving safely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005558/en/
“The global impact of the COVID-19 pandemic has shown us how critical digital transformation is in our daily lives,” said Todd Wilkinson, CEO of Entrust. “As consumers, we depend on digital technologies and security to do more than ever, whether it’s making purchases, crossing borders, accessing government services or logging into corporate networks. We are proud that some of the world’s largest governments, organizations and enterprises trust us to keep citizens, commerce and information moving safely. Making Entrust the foundation of our brand reflects how our technology and innovation are central to securing this ever-evolving world.”
The company was founded as Datacard Corporation in 1969, and acquired Entrust in 2013, becoming Entrust Datacard. Entrust today offers an unmatched breadth of solutions, including credential issuance, identity and data protection, and digital certificates and signing solutions.
Commitment to innovation and growth
In recent years, Entrust has expanded from its core physical credential issuance focus to build a robust digital security solution portfolio and market presence. In addition to a sustained long-term investment in R&D, the company has made a recent series of strategic acquisitions, including PKI providers Trustis and Safelayer, authentication provider SMS Passcode, and nCipher, the market leader in hardware security modules (HSMs).
As a result, Entrust has transformed into one of the world’s largest providers of digital security software, and the global leader in credential issuance solutions. The company is in a unique position to innovate and invest to meet the rising security and identity needs of its customers. Entrust is making significant R&D investments to bring to market new card issuance technology, secure cloud enablement and advancements to its authentication, digital signing, identity management and HSM solutions. The company recently launched its next-generation PKI platform , tailored to meet today’s rising “encrypt everything” demands amidst rising threats, and earlier this year introduced new solutions for passwordless authentication and digital onboarding .
With nearly $800M in annual revenue and 2,500 employees, Entrust is trusted by some of the world’s most demanding, compliance-driven institutions in finance, technology and government. The company provides sales and service in more than 150 countries through 50 offices and a global network of more than 1,000 technology and channel partners.
“Earning the benefits of digital transformation requires a foundation of trust. As identity, payment and data protection ecosystems become more complex and interconnected, trust enables the resiliency and scale needed to make our digital lives possible,” said Frank Dickson, Program VP, Cybersecurity Products, IDC. “Entrust began delivering trust in payment card solutions 50 years ago and has added breadth and depth to its trusted identity and data security solutions ever since. Thus, centering the brand on Entrust makes sense – it helps the market see the common thread of high-assurance trust-building technology that carries through all of its identity, payment and data protection solutions.”
A simplified, refreshed brand
Entrust’s new name and branding honors the company’s heritage as it looks ahead. Datacard will continue to be featured prominently as the product line name for the company’s high-volume card issuance solutions, and the company continues to invest and innovate in high-volume hardware, software, services and supplies. Similarly, while the nCipher name will transition to Entrust over time, the nShield product line name for its market-leading HSMs will be retained and become an Entrust product line.
The branding evolution includes a new logo, brand colors, website, tagline, and positioning that are tightly linked to Entrust’s focus on securing a rapidly changing world.
“In evolving our brand, we wanted to make our mission clear. We come to work every day with one thing in mind: delivering solutions that enable the highest level of trust in every interaction our customers facilitate. Enabling trust is our mission, our value proposition, and the focus of all the innovative technologies we continue to develop for clients worldwide,” said Karen Kaukol, Chief Marketing Officer, Entrust.
To explore the new brand and learn more about Entrust’s products and services, visit www.entrust.com .
About Entrust
Entrust keeps the world moving safely by enabling trusted identities, payments and data protection. Today more than ever, people demand seamless, secure experiences, whether they’re crossing borders, making a purchase, accessing e-government services or logging into corporate networks. Entrust offers an unmatched breadth of digital security and credential issuance solutions at the very heart of all these interactions. With more than 2,500 colleagues, a network of global partners, and customers in over 150 countries, it’s no wonder the world’s most entrusted organizations trust us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005558/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
